Nicoletto M O, Fiorentino M V, Vinante O, Prosperi A, Tredese F, Tumolo S, Cima G P, Monfardini S
Division of Medical Oncology, University Hospital, Padua, Italy.
Oncology. 1992;49(6):467-73. doi: 10.1159/000227094.
Eighteen patients affected with epithelial ovarian cancer have been treated by intraperitoneal alpha 2a-Interferon. The usual single dosage was 54 x 10(6) U at weekly intervals for four times (eight times in responders): 10 histologically confirmed complete remissions and 3 partial remissions have been obtained; the toxicity was represented by fever in the majority of the cases, by abdominal discomfort in some cases, and by a mild transitory neurological complication in 1 case. Seventeen of 18 patients were pretreated, and 11 of 18 had only cytologic and/or microscopic disease. alpha 2a-Interferon has proven to be very effective and moderately toxic in microscopic peritoneal disease of ovarian epithelial cancer previously treated with extensive surgery and intravenous cytotoxic chemotherapy.
18例上皮性卵巢癌患者接受了腹腔内α2a干扰素治疗。通常的单次剂量为54×10⁶单位，每周一次，共四次（反应者为八次）；已获得10例组织学确诊的完全缓解和3例部分缓解；毒性表现为大多数病例出现发热，部分病例出现腹部不适，1例出现轻度短暂性神经并发症。18例患者中有17例接受了预处理，18例中有11例仅存在细胞学和/或显微镜下疾病。α2a干扰素已被证明对先前接受广泛手术和静脉细胞毒性化疗的卵巢上皮癌微小腹膜疾病非常有效且毒性中等。
